Skip to main content

Blood Diseases: Drugs

Question for Department of Health

UIN 12558, tabled on 20 October 2015

To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.

Answered on

30 October 2015

The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.


NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.




Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.